Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Early Access Scheme Likely This Year, But Funding Is An Issue

Executive Summary

UK patients may benefit later this year from a new scheme granting early access to certain new medicines prior to formal approval. But one stumbling block is that the government will not provide funding for drugs used under the program

You may also be interested in...



U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy

Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.

Prime Minister Cameron Plans To Boost U.K. Biotech With New "Catalyst" Fund, Early Patient Access Scheme

The U.K. plans to boost its life sciences sector with a series of measures, including a fund to support early-stage research and allowing early access to innovative medicines before regulatory approval.

Defining Innovation: UK's NICE Responds To Recent Criticism Over Its Methods

The watchdog will discuss its proposals at a regularly scheduling public meeting on Sept. 16.

Related Content

Topics

UsernamePublicRestriction

Register

PS051858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel